MAPK8 and breast carcinoma: This analysis revealed a significant enrichment of JNK signature genes in patients who responded poorly to the therapy, as compared to those that showed a pathological complete response (pCR), suggesting that JNK activity promotes chemoresistance in patients with breast cancer (Fig 7F).